09 January 2019
IntegraGen announced today its unaudited annual sales revenue for 2018.
Sales revenue of €6.9 million (+11%) Very strong increase (+29%) in sequencing services for the R&D segment Strong reduction in cash consumption. Cash position of €4.0 million as of December 31, 2018 Commercial launch of SIRIUS and MERCURY online genomic data (…) »
12 November 2018
IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools. (…) »
20 September 2018
IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018.
Sales revenue: 3.7 M€, +17% vs. H1 2017 Significant growth in genomics services Operating profit: -0.5 M€, + 57% vs. (…) »
04 September 2018
IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation of miR-31-3p Expression Level to Predict (…) »
31 July 2018
IntegraGen has announced that it has been selected by the Sequencing Omics Information Analysis (SeqOIA) Cooperative Health Group (GCS) for the operation of its high throughput sequencing platform. The SeqOIA GCS, which includes the Assistance Publique- Hôpitaux de Paris, the Institut Curie and the Gustave Roussy Cancer Center, (…) »
23 April 2018
IntegraGen announced that it has earned ISO 13485:2016 certification from Bureau Veritas. This certification indicates that the company’s quality management systems meet the specific standards required for the design, development, production and marketing of in vitro diagnostic kits, and lays the foundation for a continuous improvement process for in (…) »
13 April 2018
IntegraGen has announced the company’s financial results for the year ending December 31, 2017. The annual accounts were approved by the Board of Directors held on April 12, 2018.
Click here to view press release.
12 April 2018
IntegraGen announced that it presented data on several proprietary microRNA biomarkers during the 2018 European Lung Cancer Conference (ELCC) being held in Geneva, Switzerland. Based on an analysis of liquid biopsy samples from 133 patients with advanced squamous cell carcinoma of the lung enrolled in the Lux-Lung 8 Phase III (…) »
14 February 2018
IntegraGen announces a global distribution agreement with Twist Bioscience for IntegraGen’s portfolio of genomic data analysis tools. The agreement includes distribution rights for SIRIUS™, an online Big Data solution that assists researchers to quickly and intuitively analyze exome data for Mendelian and oncology applications, and MERCURY™, an online (…) »
25 January 2018
IntegraGen today announced the addition of Twist Bioscience Corporation’s Human Core Exome Complete Kit, a streamlined library prep and exome enrichment solution, to its next-generation targeted sequencing product offerings. Under the terms of the agreement Twist Bioscience will provide IntegraGen its Human Core Exome Complete Kit for all target (…) »